BioMerieux and Quanterix have entered into a strategic agreement that gives BioMerieux exclusive rights to Quanterix's Simoa technology in clinical labs and for industrial applications. BioMerieux will develop ultra-sensitive and multiplex assays using the Simoa platform, with a particular focus on infectious diseases. Quanterix will receive upfront and milestone payments, as well as royalties on future sales. Additionally, BioMerieux has taken an initial $15 million equity stake in Quanterix.
The Simoa technology is based on a digital approach that enables detection of a signal from single molecules of a labelled analyte, and is much more sensitive than conventional analog-based protein detection technologies, according to the company.
"This agreement marks an important milestone for our immunoassay franchise, strengthening our role as a specialized player with a ground-breaking technology that delivers significant medical value," said Jean-Luc Belingard, chairman and chief executive officer of BioMerieux. "We have great admiration for Quanterix's achievement in developing a technology with the sensitivity of molecular diagnostics at a more affordable cost. We are very pleased to make this breakthrough available to a broad number of laboratories."
"BioMerieux's partnership validates the incredible foundation the Quanterix team has developed and will make it possible for this remarkable technology to make a difference in the lives of patients," said Paul Chapman, president and chief executive officer of Quanterix. "As one of the leading companies in the IVD space, we could not have found a better strategic partner to develop and commercialize Simoa in this critical market segment."
BioMerieux, Quanterix In Strategic Immunoassay Pact
Published November 16, 2012
blog comments powered by Disqus